There’s a fortune to be made in new pharma

Educated investors could see huge financial benefits ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

FG CDMG GT Bio Internal Email Series - #2

by Jason Williams / november 29, 2025 There’s a fortune to be made in new pharma Dear Reader, A Perfect Storm is brewing... again. Remember five years ago, when “Operation Warp Speed” turned vaccine research companies into mega-winners for investors? Today, you can combine the restructuring of government spending on revolutionary new therapies, an aging population, and skyrocketing cancer rates worldwide, the time is ripe for small medical research companies to reap the rewards for early investors. During my forecasting of this new Perfect Storm, I found one such small company.  They created a revolutionary new cancer immunotherapy that empowers the body’s own defenses to kill cancer cells. I published a must-read for every investor who wants to ride the new tidal wave coming to the healthcare industry with this company. Click here for the full story. To your wealth, Jason Williams Investment Director, Future Giants Feedback? get in touch Read this email online Manage Newsletters Share on Twitter You signed up for our newsletter with the email indra21poetra@gmail.com. You can manage your subscription and get our privacy policy here. This email is from Angel Publishing, 3 East Read Street, Baltimore, MD 21202 © Wealth Daily.